Archive: Company News
Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor
— Claus Andersson, PhD, joins Rewind´s Board of Directors
Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that it has raised additional funding, with Sunstone Life Science Ventures A/S joining as a new investor and with participation of existing investors Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven.
Claus Andersson, PhD, General Partner at Sunstone Life Science Ventures A/S, will join Rewind Therapeutics´ Board of Directors. Financial details of the transaction were not disclosed.
ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002
– Lead compound IOS-1002 to be studied as mono and combination therapy in patients with advanced solid tumors
– First patients to be enrolled in Q1, 2023
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced that the Company has received full ethical institutional approval from the Human Research Ethics Committee (HREC) and regulatory approval from the Therapeutic Goods Administration (TGA) to conduct a Phase 1 trial of its lead program IOS-1002 in Australia. The first patients are expected to be enrolled in Q1, 2023.
Pan Cancer T Appoints Dr. Rachel Abbott as Chief Scientific Officer
– Strengthening of T cell research expertise to develop next-generation T cell therapies for patients with limited or no treatment options
Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announced the appointment of Dr. Rachel Abbott as Chief Scientific Officer.
Dr. Abbott will succeed Pan Cancer T co-founder Prof. Reno Debets, who will continue supporting the Company from his academic position as Head of the Laboratory of Tumor Immunology at Erasmus MC. Prior to joining Pan Cancer T, Rachel Abbott had been Senior Director, Head of TCR Pipeline and Dark Antigen Research at Enara Bio from March 2021 to January 2023. In this role, she was responsible for building and delivering on strategic research frameworks, with a particular focus on the discovery and validation of so-called dark antigens, i.e., unconventional cancer immunotherapy targets that arise from the aberrant transcription of normally silenced regions of genomic dark matter. Read more…
